Dataset from A Randomized, Open Label, 2-Period, 2-Treatment, Cross-over Phase 1 Study to Evaluate the Bio-equivalence of Single Oral Dose of TAK-536 Pediatric Formulation and TAK-536 Commercial Formulation in Healthy Adult Male Subjects
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00007568
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the bio-equivalence of a single oral administration
of TAK-536 pediatric formulation (granules) in comparison with a TAK-536 commercial
formulation (tablet) in Japanese healthy adult male participants in an open label, 2-period,
2-treatment, cross-over design.
创建时间：
2025-10-01
